Characteristics and Outcomes of Women Developing Heart Failure After Early Stage Breast Cancer Chemotherapy: A Population-Based Matched Cohort Study

Figures

• 

  Figure 1.. Cumulative incidence of hospital presentations for heart failure (HF), depicted in blue for women treated with anthracyclines without trastuzumab and red for cancer-free controls who were matched on age, year of HF diagnosis, setting of HF diagnosis, ischemic heart disease, acute myocardial infarction, valvular disease, hypertension, diabetes, and chronic kidney disease. EBC indicates early stage breast cancer.

• 

  Figure 2.. Cumulative incidence of hospital presentations for heart failure (HF), depicted in blue for women treated with trastuzumab (but not anthracyclines) and red for cancer-free controls who were matched on age, year of HF diagnosis, setting of HF diagnosis, ischemic heart disease, acute myocardial infarction, valvular disease, hypertension, diabetes, and chronic kidney disease. EBC indicates early stage breast cancer.

• 

  Figure 3.. Cumulative incidence of hospital presentations for heart failure (HF), depicted in blue for women who received sequential therapy and red for cancer-free controls who were matched on age, year of HF diagnosis, setting of HF diagnosis, ischemic heart disease, acute myocardial infarction, valvular disease, hypertension, diabetes, and chronic kidney disease. EBC indicates early stage breast cancer.

• 

  Figure 4.. Summary of the results of sensitivity analyses for women who developed heart failure (HF) after exposure to anthracyclines without trastuzumab and their matched controls (left) and women who developed HF after exposure to trastuzumab (with and without anthracyclines) and their matched controls (right). We present the hazard ratio associated with early stage breast cancer (EBC) status from Fine-Gray regression models limited to EBC-HF patients in each subgroup and their matched controls. EBC indicates early stage breast cancer; and ED, emergency department.

• 

  Figure 5.. Cumulative incidence of cardiovascular death, depicted in blue for the anthracycline-heart failure (HF) cohort and red for cancer-free controls who were matched on age, year of HF diagnosis, setting of HF diagnosis, ischemic heart disease, acute myocardial infarction, valvular disease, hypertension, diabetes, and chronic kidney disease. EBC indicates early stage breast cancer.

• 

  Figure 6.. Cumulative incidence of cardiovascular death, depicted in blue for a combination of the trastuzumab-heart failure (HF) and sequential-HF groups, and red for cancer-free controls who were matched on age, year of HF diagnosis, setting of HF diagnosis, ischemic heart disease, acute myocardial infarction, valvular disease, hypertension, diabetes, and chronic kidney disease. EBC indicates early stage breast cancer.

• 

  Figure 7.. Graphical abstract summarizing overall study findings. EBC indicates early stage breast cancer; and HF, heart failure.